Johnson & Johnson (JNJ) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $240.01 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.3% away).
Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine (prescription therapies across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular/metabolism) and MedTech... Read more
Sell if holding. Analyst target reached at $240.01 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.3% away). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 5.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson generated approximately $88.8 billion of fiscal 2025 sales across two segments, Innovative Medicine and MedTech, with 43% of revenue sourced outside the United States (23% Europe, 15% Asia-Pacific and Africa, 5% Western Hemisphere ex-US). The DARZALEX franchise alone accounted for 15.0% of total revenues, STELARA contributed 6.5% and TREMFYA delivered 5.5%, anchoring an oncology, immunology and neuroscience-led therapeutic mix supported by 138,200 full-time-equivalent positions worldwide.
The Innovative Medicine segment distributes prescription medicines directly to retailers, wholesalers, distributors, hospitals and healthcare professionals, with concentrated revenue in CAR-T therapy CARVYKTI, daratumumab franchises DARZALEX and DARZALEX FASPRO, prostate-cancer agent ERLEADA, bispecifics TALVEY and TECVAYLI, IL-23 inhibitor TREMFYA, and oral anticoagulant XARELTO co-marketed with Bayer. The MedTech segment sells through hospitals, surgical centers and eye-care professionals, spanning electrophysiology, the Abiomed mechanical circulatory support portfolio, the Shockwave intravascular lithotripsy business, orthopaedics, surgery (including Mentor breast aesthetics) and the ACUVUE contact-lens and TECNIS intraocular-lens vision portfolios. Manufacturing runs through 63 facilities sourcing from thousands of suppliers, with third-party manufacturers producing certain raw materials, component parts and finished products. New products launched within the past five years contributed 25% of 2025 sales, and in October 2025 the company announced its intention to separate the Orthopaedics business, targeting completion within 18 to 24 months after the initial announcement.
Show full overview
The patent-cliff and IRA-pricing lens dominates the forward setup. STELARA, the second-largest product at 6.5% of revenue, faces ongoing global biosimilar launches the filing expects will continue to weigh on STELARA sales, while DARZALEX compound patents expire in the United States in 2029 with royalties to Genmab A/S of $2.4 billion paid in fiscal 2025. XARELTO and STELARA appear on the first CMS Selected Drug list with Medicare Part D pricing beginning in 2026, and in January 2026 CMS added ERLEADA to the 2028 list, pending Janssen's December 2025 U.S. Supreme Court petition challenging the IRA program. Talc litigation involving JOHNSON'S Baby Powder remains an additional overhang where the company self-insures via a captive.
See also: Healthcare · Drug Manufacturers - General
From Johnson & Johnson's most recent 10-K filing, extracted May 16, 2026.
Recent developments
updated 2026-06-15Recent Developments — Johnson & Johnson
Latest news
- NEWS Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results - Business Wire — Business Wire neutral
- NEWS Why We Increased The Position In Johnson & Johnson (JNJ) - Seeking Alpha — Seeking Alpha positive
- NEWS Is Johnson & Johnson Stock Outperforming the Dow? - Barchart.com — Barchart.com positive
- NEWS Johnson & Johnson (JNJ) Shares Fall 2.4% -- What GF Score of 87 Tells Investors - GuruFocus — GuruFocus negative
- NEWS Johnson & Johnson (JNJ) Stock Analysis: Exploring a 12.22% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk — DirectorsTalk Interviews positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $240.01 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (4.3% away). Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $231.75. Score 5.3/10, moderate confidence.
Take-profit target: $236.77 (-1.7% upside). Prior stop was $231.75. Stop-loss: $231.75.
Analyst target reached - limited upside remaining; Near 52-week high (4.3% away); Weak growth.
Johnson & Johnson trades at a P/E of 27.9 (forward 18.9). TrendMatrix value score: 4.5/10. Verdict: Sell.
31 analysts cover JNJ with a consensus score of 3.9/5. Average price target: $253.
What does Johnson & Johnson do?Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine...
Johnson & Johnson develops, manufactures and sells healthcare products through two segments: Innovative Medicine (prescription therapies across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular/metabolism) and MedTech (cardiovascular, orthopaedics, surgery and vision products). The company sells medicines to retailers, wholesalers, distributors, hospitals and healthcare professionals, and distributes MedTech products to hospitals, surgical centers and eye care professionals worldwide. In fiscal 2025, 43% of sales occurred outside the United Stat